February 19, 2013 Program
· Prof. Dr. Wolfgang W. Renz, Corporate Vice President, Boehringer Ingelheim GmbH
Dr. Renz will speak about The Future of Healthcare – Perspectives of “Connected Health” Approaches
Prof. Dr. Wolfgang Renz is an expert in the health care & pharmaceutical research fields, and is currently serving as Corporate Vice President of Business Model & HealthCare Innovation at Boehringer Ingelheim, one of the world’s largest pharmaceutical companies. Renz has worked over a decade in developing medicines and technology to help people lead healthier, more productive lives. In his present position at Boehringer Ingelheim, he is leading a team of specialists to find, test and develop the disruptive technologies that will shape the way healthcare will be delivered to all of us in the future. In addition to his current industry position, Renz also has an active role in other distinguished organizations, including Adjunct Professor of Surgery at McGill University’s Faculty of Medicine, as well as within the leadership of other innovative and future-thinking professional associations.
Previous to his role at Boehringer Ingelheim, Renz served on a variety of posts of ever increasing responsibility including CEO and General Manager of several companies, clinical research organizations, biotechnology and public pharmaceutical companies. Renz holds a medical degree and a Ph.D. from Freiburg University and is board certified in Germany in emergency medicine.
· Oded Kraft, Vice President of Products, Medingo Roche Israel, IDS
Mr. Kraft is a Vice President of Products at Medingo, an Israel-based medical devices company, which was acquired by Roche in 2010. He joined Medingo in June 2008 after working for seven years at GE Healthcare in a Segment Leader position and, prior to that, as a System Architect. Mr. Kraft holds an MBA and a BSc in Electrical Engineering from Technion–Israel Institute of Technology.
Mr. Kraft will speak about Integration of an Israeli Start-Up into a European Big Pharma Company
Dr. Rainer Lichtenberger, Managing Director / CFO/COO, CEVEC Pharmaceuticals GmbH
Rainer Lichtenberger has more than 20 years of management experience in renowned companies. Being Pharmacist by training, he joined Merck KGaA in 1988 after finishing his Ph.D. thesis in Pharmaceutical Technology. With Merck KGaA, he held various positions of increasing responsibility in R&D, project management and global marketing, among them head of the business unit „Osteoporosis & Women’s Health” and corporate vice president of global marketing. In 2002, Rainer joined the Merckle/ratiopharm group on an executive board level, in his role as corporate senior vice president business development and international marketing. Since 2004, he has been focusing on establishing start-up companies, such as Neuraxo Biopharmaceuticals GmbH, and managed a series A venture round with 12 Mio € in 2005. After Neuraxo, he joined CEVEC in late 2008 as managing director and CEO. Rainer was responsible to raise more than 12 Mio equity for CEVEC between 2009 and 2012. Together with his colleague Wolfgang Kintzel, CEO, Rainer’s mission in his current function as CFO/COO is to organize the growth of the company and to raise additional funds for CEVECs proprietary development projects in the vaccine space. Rainer holds an Executive MBA with Ashridge Management College (UK).
Thomas Exel, CCO 4a medico GmbH
4a medicom is a medtech company developing first-in-class, IP protected blood glucose monitoring devices GlucoPEARLTM, thus allowing diabetics and health care professionals to monitor the blood glucose level safe, easy and fast.
Thomas Exel, CCO:
University of Economics, Vienna; senior management positions in medical technology companies, most recently with mid-sized Diabetes-focused sales organization.
Thomas Exel joined the 4a medicom management team in November 2009 and is responsible for marketing and sales. Before his move to 4a medicom, Mr. Exel was employed for over six years as marketing and sales manager at an Austria-based medical technology company with operations throughout Europe in the diabetes field. There, he not only developed his own product line for diabetics but also ensured the sales success of the company. Thanks to his extensive international experience, and apart from his excellent product knowledge and management experience in medical technology, Mr. Exel can also call upon numerous national and international contacts in the diabetes area and bring them along to 4a medicom.
· Kaye Scholer LLP – Dr. Gottfried Freier
· Perelson Weiner LLP – John Lieberman
· Hessen Trade & Invest GmbH – Dr. Thomas Niemann
· German Center for Research and Innovation – Dr. Joann Halpern